Jan B. Vermorken - Concepedia

Author

Jan B. Vermorken

Also Known As

3) Vermorken J. B., Carlos Surez, Gauthier Desuter, J B Vermorken, J Vermorken, J. B. VERMORKEN, J. B. Vermorken, J. Vermorken, J.B Vermorken, J.B. VERMORKEN

571

Publications

18.6K

Citations

H-Index

175

Concepts

All Affiliations

Antwerp University Hospital University of Antwerp University of Amsterdam Vrije Universiteit Amsterdam The Netherlands Cancer Institute

About

Jan B. Vermorken is an author at Antwerp University Hospital specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	44	129	7.8K
2	Health Sciences	20	32	1.6K
3	Public Health	7	7	704
4	Natural Sciences	5	5	420
5	Engineering	1	1	129

Jan B. Vermorken

206

Publications

12.8K

Citations

H-Index

Page 1

	Year	Citations
Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) Gordon John Sampson Rustin, Ignace Vergote, Elizabeth A. Eisenhauer, International Journal of Gynecological Cancer	2011	600
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial Jan B. Vermorken, A.M.E. Claessen, Harm van Tinteren, The Lancet Tumor ImmunologyCancer ImmunosurveillanceStage IiMedicineRandomised Trial	1999	502
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) Andreas du Bois, Michael Quinn, Tate Thigpen, Annals of Oncology MedicineCancer ManagementReproductive HealthGynecologyGcig Occc 2004	2005	465
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial Jan B. Vermorken, Jan Stöhlmacher-Williams, Lisa Licitra, The Lancet Oncology Metastatic Squamous-cell CarcinomaOpen-label Phase 3MedicinePathologyHead And Neck Cancer	2013	432
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial Jean-Pascal H. Machiels, Robert I. Haddad, Jérôme Fayette, The Lancet Oncology Neoadjuvant TherapyNeck 1Randomised Phase 3MedicineHead And Neck Cancer	2015	386
Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy Yu‐Pei Chen, Yuan-min Wang, Jia Lv, Annals of Oncology	2018	302
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials Ignace Vergote, Corneel Coens, Matthew Nankivell, The Lancet Oncology Surgical OncologyGynecological SurgeryIndividual Patient DataMedicineChorus Trials	2018	290
Paclitaxel-induced neuropathy T.J. Postma, Jan B. Vermorken, A.J.M. Liefting, Annals of Oncology	1995	267
2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines Veronique W.T. Ruiz van Haperen, Gijsbert Veerman, Jan B. Vermorken, Biochemical Pharmacology Nucleic Acid ChemistryNatural SciencesNucleic Acid BiochemistryOligonucleotideDna Replication	1993	251
Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients Vanessa Deschoolmeester, Marc Baay, Eric Van Marck, BMC Immunology	2010	230

Page 1